Imovane
(Zopiclone)Phase 3Small molecule
Zopiclone is a sleeping pill used to treat insomnia by helping people fall asleep and stay asleep through the night.[1] Imovane is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
Imovane is one of 165 small molecule programs targeting Sleep. It is currently in Phase 3.
6
Indications
24
Total Trials
0
Active Trials
164
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Imovane
TTaisho Pharmaceutical Co., Ltd.
Phase 3
Quetiapine XR
AstraZenecaPhase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Clozaril
LLife Extension Foundation Inc.
Phase 3
Fetzima
AbbViePhase 3
Lisdexamfetamine Dimesylate
TakedaPhase 3
Desvenlafaxine SR
PfizerPhase 3
Rapastinel
AbbViePhase 3
DVS-233
PfizerPhase 3
Seroquel IR
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Insomnia5 trials
Driving5 trials
Elderly3 trials
9 more indications
Single Dose1 trial
Cardiovascular1 trial
Sleep1 trial
Major Depressive Disorder1 trial
Function1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zopiclone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- GABA-a Receptor; Agonist GABA Site Positive Allosteric Modulator[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTaisho Pharmaceutical Co., Ltd.